Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary NeuroMetrix Reports Q2 2020 Financial Results
WOBURN, Mass. , July 23, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended June 30, 2020 . The Company is a leading developer of neurostimulation-based medical devices that are used to diagnose and treat chronic health
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for Second Quarter 2020 Financial Results Conference Call
WOBURN, Mass. , July 16, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 second quarter financial results before the opening of the market on Thursday, July 23, 2020 . The Company will host a conference call at 8:00 a.m., Eastern Time on July
View HTML
Toggle Summary NeuroMetrix Reports DPNCheck® Expansion in China
WOBURN, Mass. , July 09, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced expanded distribution in China for DPNCheck, a fast, accurate and quantitative nerve conduction test for evaluation of peripheral neuropathies such as diabetic peripheral neuropathy (DPN).
View HTML
Toggle Summary NeuroMetrix Signs DPNCheck® Collaboration Agreement with Biomedix
WOBURN, Mass. , June 25, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it has signed a collaboration agreement with Biomedix to comarket DPNCheck for peripheral neuropathy detection within Medicare Advantage and other value-based care markets.
View HTML
Toggle Summary NeuroMetrix to Target Chronic Knee Pain with Quell® 2.0 Wearable Pain Relief Device
WOBURN, Mass. , June 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq: NURO) today announced that it has launched a marketing initiative focusing on chronic knee pain.  This effort includes direct-to-consumer digital marketing as well as informing physicians and other health care providers
View HTML
Toggle Summary NeuroMetrix Reports Q1 2020 Financial Results
WOBURN, Mass. , April 23, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2020 .  The Company is a leading developer of neurostimulation-based medical devices that are used to diagnose and treat chronic
View HTML
Toggle Summary NeuroMetrix Reports Quell® Technology to be Used in NIH-Funded Trial Evaluating Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS) for Fibromyalgia
WOBURN, Mass. , April 16, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that Quell technology has been selected for use in a large, NIH -funded, randomized, pragmatic clinical trial of TENS for fibromyalgia.   Fibromyalgia is a disorder characterized by widespread
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for First Quarter 2020 Financial Results Conference Call
WOBURN, Mass. , April 16, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 first quarter financial results before the opening of the market on Thursday, April 23, 2020 . The Company will host a conference call at 8:00 a.m., Eastern Time on
View HTML
Toggle Summary NeuroMetrix Announces 2020 Annual Meeting of Shareholders Will Be Held in Virtual Meeting Format Only
WOBURN, Mass. , April 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that, due to the public health impact of the COVID-19 pandemic and in accordance with orders issued by the Governor of the Commonwealth of Massachusetts , the Company’s 2020 Annual Meeting of
View HTML
Toggle Summary NeuroMetrix Provides Quell® Technology Commercial Strategy and Pipeline Update
WOBURN, Mass. , March 11, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today provided an update on its Quell technology commercial strategy and pipeline. An estimated 100 million US adults have chronic pain. People with chronic pain may also have low quality sleep, anxiety, depression,
View HTML